Consolidated Financial Results for Fiscal 2015
`
`(Reference Data of Financial Statements Fiscal 2015)
`
`May 12, 2016
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
` Corporate Communications
` Tel:
` +81-(0)3-5977-5002
` Fax:
` +81-(0)3-5977-5131
` Email:
` koho@kaken.co.jp
`
`ACRUX DDS PTY LTD. et al.
`
`EXHIBIT 1646
`
`IPR Petition for
`
`U.S. Patent No. 7,214,506
`
`Page 1 of 5
`
`

`

`1. Summary of Consolidated Financial Statements for Fiscal 2015
`
`( Figures less than one million yen have been omitted)
`
`FY
`2013
`
`FY
`2014
`
`FY
`2015
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Plan
`FY2016
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Net sales
`
`88,946
`
`93,889
`
`109,730
`
`15,840
`
`116.9% 106,100
`
`(3,630)
`
`Operating income
`
`15,872
`
`20,631
`
`35,146
`
`14,515
`
`170.4%
`
`28,900
`
`(6,246)
`
`96.7%
`
`82.2%
`
` Ratio of net sales
`
`17.8%
`
`22.0%
`
`32.0%
`
`27.2%
`
`Ordinary income
`
`15,521
`
`20,394
`
`35,365
`
`14,971
`
`173.4%
`
`29,100
`
`(6,265)
`
`82.3%
`
` Ratio of net sales
`
`17.5%
`
`21.7%
`
`32.2%
`
`27.4%
`
`Net income
`
`9,735
`
`12,122
`
`21,143
`
`
`
`9,020
`
`174.4%
`
`20,800
`
`(343)
`
`98.4%
`
` Ratio of net sales
`
`10.9%
`
`12.9%
`
`19.3%
`
`Per share profit(Yen)
`
`228.27
`
`290.90
`
`510.54
`
`19.6%
`
`502.34
`
`25.3%
`
`ROE
`
`14.5%
`
`16.7%
`
`Note: Kaken has conducted a consolidation of common share at rate of one share for every two shares with effective date of October 1, 2015.
` Per share profit has been calculated as if this consolidation of shares was conducted at the bigining of fiscal year 2013.
`
`Comprehensive income
`
`10,197
`
`16,607
`
`18,444
`
`1,837
`
`111.1%
`
`Capital investment
`
`1,733
`
`2,806
`
`2,923
`
`117
`
`104.2%
`
`1,700
`
`(1,223)
`
`58.2%
`
`R&D expenses
`
`7,045
`
`7,615
`
`5,883
`
`(1,731)
`
`77.3% 10,200
`
`4,317
`
`173.4%
`
`Depreciation and amortization
`
`2,538
`
`2,400
`
`2,242
`
`(157)
`
`93.5%
`
`2,500
`
`258
`
`111.5%
`
`Employee number
`
`1,540
`
`1,503
`
`1,451
`
`(52)
`
`2. Breakdown of Consolidated Net Sales by Segment
`
`( Figures less than one million yen have been omitted)
`
`FY
`2013
`
`FY
`2014
`
`FY
`2015
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`86,483
`
`91,458
`
`107,391
`
`15,932
`
`117.4%
`
`Pharmaceuticals,
`medical devices &
`agrochemicals
`
`Real estate
`
`2,463
`
`2,431
`
`2,338
`
`(92)
`
`96.2%
`
`Total
`
`88,946
`
`93,889
`
`109,730
`
`15,840
`
`116.9%
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 2 of 5
`
`

`

`3. Summary of Consolidated Balance Sheets
`
`As of
` March 31,
`2014
`
`Ratio
`
`As of
` March 31,
`2015
`
`( Figures less than one million yen have been omitted)
`Y o Y
`increase
`(decrease)
`
`Ratio
`
`As of
` March 31,
`2016
`
`Ratio
`
`Assets
`
`106,465
`
`100.0% 115,135
`
`100.0% 132,991
`
`100.0%
`
`17,856
`
` Current assets
`
`58,501
`
`54.9%
`
`69,016
`
`59.9%
`
`88,991
`
`66.9%
`
`19,975
`
` Noncurrent assets
`
`47,964
`
`45.1%
`
`46,118
`
`40.1%
`
`43,999
`
`Liabilities
`
`38,368
`
`36.0%
`
`38,035
`
`33.0%
`
`43,116
`
` Current liabilities
`
`28,056
`
`26.4%
`
`30,369
`
`26.4%
`
`33,861
`
` Noncurrent liabilities
`
`10,312
`
`9.7%
`
`7,665
`
`6.7%
`
`9,255
`
`33.1%
`
`32.4%
`
`25.5%
`
`7.0%
`
`(2,118)
`
`5,081
`
`3,491
`
`1,589
`
`Net assets
`
`68,096
`
`64.0%
`
`77,100
`
`67.0%
`
`89,875
`
`67.6%
`
`12,775
`
`22.4%
`
`23,853
`
`20.7%
`
`23,853
`
`17.9%
`
`－
`
` Capital stock
`
`23,853
`
` Capital surplus
`
`11,587
`
`10.9%
`
`11,406
`
`9.9%
`
`11,407
`
`8.6%
`
`0
`
` Retained earnings
`
`49,789
`
`46.8%
`
`52,932
`
`46.0%
`
`68,609
`
`51.6%
`
`15,676
`
` Treasury stock
` Valuation difference
` on available-for-sale securities
`
` Remeasurements of defined
` benefit plans
`
`(17,656)
`
`(16.6%)
`
`(16,098)
`
`(14.0%)
`
`(16,301)
`
`(12.3%)
`
`(202)
`
`2,398
`
`2.3%
`
`5,478
`
`4.8%
`
`4,423
`
`3.3%
`
`(1,054)
`
`(1,876)
`
`(1.8%)
`
`(472)
`
`(0.4%)
`
`(2,117)
`
`(1.6%)
`
`(1,644)
`
`4. Summary of Consolidated Statements of Cash Flows
`
`( Figures less than one million yen have been omitted)
`Y o Y
`increase
`(decrease)
`
`FY
`2015
`
`FY
`2013
`
`FY
`2014
`
`Net cash provided by (used in) operating activities
`
`13,663
`
`14,737
`
`27,067
`
`12,329
`
`Net cash provided by (used in) investing activities
`
`(2,135)
`
`473
`
`(4,105)
`
`(4,579)
`
`Net cash provided by (used in) financing activities
`
`(10,992)
`
`(7,900)
`
`(5,984)
`
`1,916
`
`Cash and cash equivalents at end of period
`
`17,457
`
`24,767
`
`41,744
`
`16,976
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 3 of 5
`
`

`

`5. Summary of Non-consolidated Financial Statements for Fiscal 2015
`
`( Figures less than one million yen have been omitted)
`
`FY
`2013
`
`FY
`2014
`
`FY
`2015
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Plan
`FY2016
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Net sales
`
`87,101
`
`91,951
`
`107,627
`
`15,675
`
`117.0% 104,400
`
`(3,227)
`
`Operating income
`
`15,215
`
`19,994
`
`34,468
`
`14,474
`
`172.4% 28,800
`
`(5,668)
`
`97.0%
`
`83.6%
`
` Ratio of net sales
`
`17.5%
`
`21.7%
`
`32.0%
`
`27.6%
`
`Ordinary income
`
`14,957
`
`19,845
`
`34,743
`
`14,897
`
`175.1% 29,000
`
`(5,743)
`
`83.5%
`
` Ratio of net sales
`
`17.2%
`
`21.6%
`
`32.3%
`
`27.8%
`
`Net income
`
`9,395
`
`11,777
`
`18,757
`
`6,980
`
`159.3% 20,700
`
`1,943
`
`110.4%
`
` Ratio of net sales
`
`10.8%
`
`12.8%
`
`17.4%
`
`Per share profit(Yen)
`
`220.30
`
`262.61
`
`452.92
`
`19.8%
`
`499.93
`
`Note: Kaken has conducted a consolidation of common share at rate of one share for every two shares with effective date of October 1, 2015.
` Per share profit has been calculated as if this consolidation of shares was conducted at the bigining of fiscal year 2013.
`
`Capital investment
`
`1,718
`
`2,777
`
`2,897
`
`120
`
`104.3%
`
`1,700
`
`(1,197)
`
`58.7%
`
`7,045
`
`7,615
`
`5,883
`
`(1,731)
`
`77.3% 10,200
`
`4,317
`
`173.4%
`
`R&D expenses
`
`Depreciation and amortization
`
`2,459
`
`2,319
`
`2,160
`
`(158)
`
`93.2%
`
`2,500
`
`340
`
`115.7%
`
`Export volume
`
` Pharmaceuticals
`
` Agrochemicals
`
`4,992
`
`2,972
`
`2,020
`
`7,220
`
`4,813
`
`2,407
`
`10,137
`
`7,859
`
`2,277
`
`2,916
`
`3,046
`
`140.4%
`
`163.3%
`
`(129)
`
`94.6%
`
`Employee number
`
`1,523
`
`1,493
`
`1,444
`
`(49)
`
`6. Breakdown of Non-consolidated Net Sales by Segment
`
`( Figures less than one million yen have been omitted)
`
`FY
`2013
`
`FY
`2014
`
`FY
`2015
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Plan
`FY2016
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`79,941
`
`84,444
`
`100,062
`
`15,618
`
`118.5% 96,180
`
`(3,882)
`
`96.1%
`
`5,095
`
`2,064
`
`5,472
`
`2,034
`
`5,620
`
`1,944
`
`147
`
`(90)
`
`102.7%
`
`95.5%
`
`5,870
`
`2,350
`
`250
`
`406
`
`104.4%
`
`120.9%
`
`Pharmaceuticals &
`medical devices
`
`Agrochemicals
`
`Renting real estate
`
`Total
`
`87,101
`
`91,951
`
`107,627
`
`15,675
`
`117.0% 104,400
`
`(3,227)
`
`97.0%
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 4 of 5
`
`

`

`7. Breakdown of Sales by Main Pharmaceuticals and Medical Devices
`
`( Figures less than one hundred million yen have been omitted)
`
`FY
`2014
`
`FY
`2015
`
`%
`
`Plan
`FY2016
`
`%
`
`30,259
`
`30,760
`
`101.7% 29,300
`
`95.3%
`
`6,857
`
`19,868
`
`289.7% 23,800
`
`119.8%
`
`10,791
`
`11,262
`
`104.4%
`
`11,500
`
`102.1%
`
`4,373
`
`4,526
`
`103.5%
`
`4,300
`
`95.0%
`
`3,511
`
`3,617
`
`103.0%
`
`3,700
`
`102.3%
`
`Anti-osteoarthritis
`
`Artz
`
`Anti-nail fungus
`
`Clenafin
`
`Post-operative anti-adhesive
`
`Seprafilm
`
`Anti-hyperlipidemia
`
`Lipidil
`
`Wound healing agent
`
`Fiblast Spray
`
`Generic products
`
`12,380
`
`13,292
`
`107.4%
`
`12,700
`
`95.5%
`
`Sales of Jublia*
`
`3,318
`
`5,722
`
`172.4%
`
`4,100
`
`71.7%
`
`(*including sales of API and finished product, royalty revenue and milestone revenue)
`
`8. Development Status
`
`Code
`
`Indication
`
`Stage
`
`Remarks
`
`KCB-1D
`
`Periodontitis
`
`Filed
`
`bFGF
`
`KAG-308
`
`Ulcerative colitis
`
`PII
`
`Developed jointly with Asahi Glass Co.,
`Ltd.;
`Oral-use prostaglandin analog
`
`BBI-4000
`
`Primary focal
`hyperhidrosis
`
`Preparing for PII
`
`Licenced from Brickell Biotech, Inc.;
`Topical anticholinergic
`
`SI-657
`
`Enthesopathy
`
`Development
`abandoned
`
`Developed jointly with Seikagaku
`Corporation;
`Additional indication for ARTZ
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 5 of 5
`
`